Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products
Chimeric antigen receptor-engineered T cell therapies (CAR-T) are becoming powerful immunotherapeutic tools for treating malignancies, especially hematological malignancies. Like other biological drugs, CAR-T cell products can trigger unwanted immune responses in patients receiving the treatment. Th...
Saved in:
| Main Authors: | Hammodah R. Alfar, Cecil Chen, Eric Lachacz, Weifeng Tang, Yuqian Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1512494/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunogenicity Assessment of Pegfilgrastim in Patients with Breast Cancer
by: Yu. V. Medvedev, et al.
Published: (2020-05-01) -
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2024-11-01) -
Proceedings of the 15th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
by: Sophie Tourdot, et al.
Published: (2025-12-01) -
What are clinically significant anti-drug antibodies and why is it important to identify them
by: Steven James Swanson
Published: (2024-12-01) -
CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting
by: Ran Kong, et al.
Published: (2025-03-01)